InflaRx NV (InflaRx NV) ROCE % : -57.95% (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is InflaRx NV ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. InflaRx NV's annualized ROCE % for the quarter that ended in Dec. 2023 was -57.95%.

InflaRx NV ROCE % Historical Data

The historical data trend for InflaRx NV's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InflaRx NV ROCE % Chart

InflaRx NV Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-40.54

-38.52

-47.88

-29.03

-44.83

InflaRx NV Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-34.99	-52.77	-32.13	-24.20	-57.95

InflaRx NV ROCE % Calculation

InflaRx NV's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-46.491	/	( ( (108.475 - 13.799)	+	(131.089 - 18.369) )	/ 2 )
	=	-46.491	/	( (94.676	+	112.72)	/ 2 )
	=	-46.491	/	103.698
	=	-44.83 %

InflaRx NV's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-69.4	/	( ( (138.191 - 11.404)	+	(131.089 - 18.369) )	/ 2 )
	=	-69.4	/	( ( 126.787	+	112.72 )	/ 2 )
	=	-69.4	/	119.7535
	=	-57.95 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

InflaRx NV (NAS:IFRX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

InflaRx NV ROCE % Related Terms

Thank you for viewing the detailed overview of InflaRx NV's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

InflaRx NV (InflaRx NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InflaRx NV (NAS:IFRX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

IF0:Germany IF0:Germany

Address

Winzerlaer Strasse 2, Jena, DEU, 07745

Website

https://www.inflarx.de

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.